

Form PTO-1449	FEB 12 2002	U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO. 1146	SERIAL NO. 09/993,808
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)			APPLICANT Gordon-Kamm et al.	
			FILING DATE November 6, 2001	GROUP 1638

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
CC	A1	5,968,821	10/19/99	Beach et al.	435	325

FOREIGN PATENT DOCUMENTS

	Document Number	Date	Country	Class	Subclass	Translation Yes	No
CC	A2	WO 94/10300	05/11/94	PCT	C12N	15/10	X
	A3	WO 97/12060	04/03/97	PCT	C12Q	1/68	X
	A4	WO 97/16447	05/09/97	PCT	C07D	405/04	X
	A5	WO 97/26327	07/24/97	PCT	C12N	5/04	X
	A6	WO 99/06540	02/11/99	PCT	C12N	15/00	X
	A7	WO 99/13083	03/18/99	PCT	C12N	15/29	X
	A8	WO 99/14331	03/25/99	PCT	C12N	15/29	X
✓	A9	WO 00/60087	10/12/00	PCT	C12N	15/29	X

OTHER DOCUMENTS (Including Author, Title, Date Pertinent Pages, Etc.)

CC	A10	Cayrol et al., "p21 binding to a PCNA causes G1 and G2 cell cycle arrest in p53-deficient cells", <i>Oncogene</i> 16:311-310 (1998)
	A11	Grafi et al., "Endoreduplication in Maize Endosperm: Involvement of M Phase-Promoting Factor Inhibition and Induction of S Phase-Related Kinases", <i>Science</i> 269:1262-1264 (1995)
	A12	Hengst et al., "A cell cycle-regulated inhibitor of cyclin-dependent kinases", <i>Proc. Natl. Acad. Sci. USA</i> 91:5291-5295 (1994)
	A13	Lui et al., "The <i>Arabidopsis</i> Cdc2a-interacting protein ICK2 is structurally related to ICK1 and is a potent inhibitor of cyclin-dependent kinase activity <i>in vitro</i> ", <i>The Plant Journal</i> 21(4):379-385 (2000)
	A14	Peter et al., "Joining the Complex: Cyclin-Dependent Kinase Inhibitory Proteins and the Cell Cycle", <i>Cell</i> 79:181-184 (1994)
✓	A15	Wang et al., "A plant cyclin-dependent kinase inhibitor gene", <i>Nature</i> 386:451-452 (1997)
EXAMINER	DATE CONSIDERED	
10/21/04		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Form PTO-1449	U.S. Department of Commerce Patent and Trademark Office	ATTORNEY DOCKET NO. 1146	SERIAL NO. 09/993,808
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)		APPLICANT Gordon-Kamm et al.	
		FILING DATE November 6, 2001	GROUP

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate

FOREIGN PATENT DOCUMENTS


Document Number	Date	Country	Class	Subclass	Translation Yes	Translation No

OTHER DOCUMENTS (Including Author, Title, Date Pertinent Pages, Etc.)

cc	A16	Wang et al., "ICK1, a cyclin-dependent protein kinase inhibitor from Arabidopsis Thaliana interacts with both Cdc2a and CycD3, and its expression is induced by abscisic acid", <i>The Plant Journal</i> 15(4):501-510 (1998)
	A17	Buell et al., <i>GenBank Accession No. AC069145</i> , Oryza sativa chromosome 10 BAC OSJNBb0094K03 genomic sequence" (2000)
	A18	Fountain et al., "Isolation of a cDNA Encoding a G1-Cyclin-Dependent Kinase Inhibitor from Suspension-Cultured Photoautotrophic <i>Chenopodium rubrum</i> Cells (Accession No. AJ002173) (PGR 99-057) <i>Plant Physiol.</i> 120:339.
	A19	Kakimoto, T., DDBJ/EMBL/ <i>GenBank Accession No. D87545</i> , "CKI1, a histidine kinase homolog implicated in cytokinin signal transduction" (1999)
	A20	GCG:Gap Analysis - protein level
✓	A21	GCG:DNA Gap Analysis -DNA level
EXAMINER <i>Cynthia Collins</i> DATE CONSIDERED <i>10/21/04</i>		

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

PTO/SB/08a (08-03)



Approved for use through 07/31/2006, OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

(Use as many sheets as necessary)

Sheet	2	of	2
-------	---	----	---

Complete if Known

Application Number	09/993,308
Filing Date	11/06/2001
First Named Inventor	William J. Gordon-Kamm
Art Unit	1638
Examiner Name	C. COLLINS
Attorney Docket Number	1146

NON PATENT LITERATURE DOCUMENTS

RECEIVED

DEC 23 2003

Technology Center 2600

**Examiner
Signature**

Date
Considered

10/21/04


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

Applicant's unique citation designation number (optional): _____ Applicant is to place a check mark next to English language.
This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.



PTO/SB/08b(08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	09/993,808
		Filing Date	11/06/2001
		First Named Inventor	William J. Gordon-Kamm
		Art Unit	2 COLLINS
Examiner Name	1638	RECEIVED MAY 19 2004	
Attorney Docket Number	1146		
Sheet	2	of	2

NON PATENT LITERATURE DOCUMENTS			Technology Center 2000
Examiner Initials *	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
CC	A26	BUELL et al., NCBI Database Accession No. AC089145, Oryza sativa chromosome 10 BAC OSJNB0094K03 genomic sequence (2000)	
	A27	BUELL et al., NCBI Database Accession No. AAG16867, Putative cyclin-dependent kinase inhibitor (2000)	
	A28	FOUNTAIN et al., Isolation of a cDNA Encoding a G1-Cyclin-Dependent Kinase Inhibitor (ICDK) from Suspension Cultured Photoautotrophic Chenopodium rubrum L. Cells (Accession No. AJ002173), Plant Gene Register PGR99-057 (1999)	
	A29	FOUNTAIN et al., NCBI Database Accession No. CFJ002173, Chenopodium rubrum G1 cyclin-dependent kinase inhibitor mRNA (1999)	
	A30	SATO et al., EMBL Database Accession No. Q9LRY0, Similarity to cyclin-dependent kinase inhibitor protein (Cyclin-dependent kinase inhibitor 5) (2000)	
↓	A31	Larkins et al., Investing the hows and whys of DNA endoreduplication, Journal of Experimental Botany 52(355):183-192 (2001)	

Examiner Signature	<i>Cynthia Collins</i>	Date Considered	10/21/04
--------------------	------------------------	-----------------	----------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.